A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Conditions
Leukemia · Leukemia, Myeloid · Leukemia, Myeloid, Acute · Preleukemia · Myelodysplastic Syndromes · Refractory Acute Myeloid Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope Medical Center, Duarte, California, United States
University of California Los Angeles, Los Angeles, California, United States
Stanford Cancer Center, Palo Alto, California, United States
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago, Illinois, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus, Ohio, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
Study leads
Sponsor Contact
Study Director
BlossomHill Therapeutics, Inc.